NANO MRNA CO.,LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181 JPY | +2.84% |
|
+1.12% | -4.74% |
| 2023 | NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases | MT |
| 2023 | NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery | CI |
Valuation
| Fiscal Period: March | 2023 |
|---|---|
| Capitalization 1 | 16,835 |
| Enterprise Value (EV) 1 | 13,500 |
| P/E ratio | -12.8 x |
| Yield | - |
| Capitalization / Revenue | 83.3 x |
| EV / Revenue | 66.8 x |
| EV / EBITDA | - |
| EV / FCF | - |
| FCF Yield | - |
| Price to Book | 3.96 x |
| Nbr of stocks (in thousands) | 70,146 |
| Reference price 2 | 240.0 |
| Announcement Date | 6/30/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 |
|---|---|
| Net sales 1 | 202 |
| EBITDA | - |
| EBIT 1 | -1,246 |
| Operating Margin | -616.83% |
| Earnings before Tax (EBT) 1 | -1,308 |
| Net income 1 | -1,310 |
| Net margin | -648.51% |
| EPS 2 | -18.69 |
| Free Cash Flow | - |
| FCF margin | - |
| FCF Conversion (EBITDA) | - |
| FCF Conversion (Net income) | - |
| Dividend per Share | - |
| Announcement Date | 6/30/23 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 |
|---|---|---|---|---|---|
| Net sales 1 | 293 | 193 | 134 | 66 | 20 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | -683 | -510 | -1,032 | -472 | -397 |
| Operating Margin | -233.11% | -264.25% | -770.15% | -715.15% | -1,985% |
| Earnings before Tax (EBT) 1 | -894 | -2,080 | -973 | -437 | -327 |
| Net income 1 | -896 | -2,082 | -975 | -437 | -327 |
| Net margin | -305.8% | -1,078.76% | -727.61% | -662.12% | -1,635% |
| EPS 2 | -15.75 | -31.22 | -13.95 | -6.250 | -4.680 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 11/14/19 | 11/12/20 | 11/12/21 | 2/10/22 | 8/10/22 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 |
|---|---|
| Net Debt 1 | - |
| Net Cash position 1 | 3,335 |
| Leverage (Debt/EBITDA) | - |
| Free Cash Flow | - |
| ROE (net income / shareholders' equity) | - |
| ROA (Net income/ Total Assets) | - |
| Assets 1 | - |
| Book Value Per Share 2 | 60.60 |
| Cash Flow per Share 2 | 40.10 |
| Capex | - |
| Capex / Sales | - |
| Announcement Date | 6/30/23 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.74% | 79.06M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.43% | 22.18B | |
| -16.67% | 21.2B | |
| -8.68% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- 4571 Stock
- Financials NANO MRNA Co.,Ltd.
